The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: Negative implications for the use of a model in screening for mood stabilizers

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 4, 2009, Pages 649-654

  Kelly, Michele P ^a   Logue, Sheree F ^a   Dwyer, Jason M ^a   Beyer, Chad E ^a   Majchrowski, Heather ^a   Cai, Zhang ^a   Liu, Zhi ^a   Adedoyin, Adedayo ^a   Rosenzweig Lipson, Sharon ^a   Comery, Thomas A ^a  

^a Discovery Research   (United States)

Author keywords

Anxiety; Bipolar disorder; Chlordiazepoxide; Locomotor activity; Mania; Mood stabilizer; Valproic acid

Indexed keywords

AMPHETAMINE; CHLORDIAZEPOXIDE; MOOD STABILIZER; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MIXTURE; DRUG POTENTIATION; DRUG SCREENING; HYPERACTIVITY; LOCOMOTION; MALE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

AFFECT; AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; ANXIETY; BIPOLAR DISORDER; CHLORDIAZEPOXIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; MALE; MICE; MICE, INBRED C57BL; MODELS, NEUROLOGICAL; MOTOR ACTIVITY; VALPROIC ACID;

MUS;

EID: 67349155577     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.03.003     Document Type: Article

References (42)

1. Agmo A., Belzung C., and Rodriguez C. A rat model of distractibility: effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission. J Neural Transm 104 (1997) 11-29
2. Arban R., Maraia G., Brackenborough K., Winyard L., Wilson A., Gerrard P., et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158 (2005) 123-132
3. Aron C., Simon P., Larousse C., and Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10 (1971) 459-469
4. Aylmer C.G., Steinberg H., and Webster R.A. Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?. Psychopharmacology 91 (1987) 198-206
5. Bielau H., Steiner J., Mawrin C., Trubner K., Brisch R., Meyer-Lotz G., et al. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann NY Acad Sci 1096 (2007) 157-169
6. Biello S.M., and Mrosovsky N. Circadian phase-shifts induced by chlordiazepoxide without increased locomotor activity. Brain Res 622 (1993) 58-62
7. Boylan K.R., Bieling P.J., Marriott M., Begin H., Young L.T., and MacQueen G.M. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 65 (2004) 1106-1113
8. Cannon D.M., Ichise M., Fromm S.J., Nugent A.C., Rollis D., Gandhi S.K., et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 60 (2006) 207-217
9. Cao B.J., and Peng N.A. Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol 237 (1993) 177-181
10. Cryan J.F., and Slattery D.A. Animal models of mood disorders: recent developments. Curr Opin Psychiatry 20 (2007) 1-7
11. Dubovsky S.L. Treatment of bipolar depression. Psychiatr Clin North Am 28 (2005) 349-370
12. Einat H. Modelling facets of mania-new directions related to the notion of endophenotypes. J Psychopharmacol 20 (2006) 714-722
13. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 37 (2007) 244-255
14. Emilien G., Septien L., Brisard C., Corruble E., and Bourin M. Bipolar disorder: how far are we from a rigorous definition and effective management?. Prog Neuro-Psychopharmacol Biol Psychiatry 31 (2007) 975-996
15. Evenden J., and Ko T. The psychopharmacology of impulsive behaviour in rats VIII: effects of amphetamine, methylphenidate, and other drugs on responding maintained by a fixed consecutive number avoidance schedule. Psychopharmacology 180 (2005) 294-305
16. Foreman M.M., Hanania T., Stratton S.C., Wilcox K.S., White H.S., Stables J.P., et al. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol Biochem Behav 89 (2008) 523-534
17. Goldberg J.F., Perlis R.H., Ghaemi S.N., Calabrese J.R., Bowden C.L., Wisniewski S., et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 164 (2007) 1348-1355
18. Gould T.D., and Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 31 (2007) 825-831
19. Gould T.D., O'Donnell K.C., Picchini A.M., and Manji H.K. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32 (2007) 1321-1333
20. Gould T.D., O'Donnell K.C., Dow E.R., Du J., and Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropsychopharmacology 54 (2008) 577-587
21. Hantouche E.G., and Akiskal H.S. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord 84 (2005) 127-132
22. Hogan J.B., Hodges Jr. D.B., Lelas S., Gilligan P.J., McElroy J.F., and Lindner M.D. Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests. Psychopharmacology 178 (2005) 410-419
23. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., et al. The long-term natural history of the weekly symptomatic status of bipolar I dirsorder. Arch Gen Psychiatry 59 (2002) 530-537
24. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 60 (2003) 261-269
25. Keller M.B. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry 67 Suppl 1 (2006) 5-7
26. Kozikowski A.P., Gaisina I.N., Yuan H., Petukhov P.A., Blond S.Y., Fedolak A., et al. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 129 (2007) 8328-8332
27. Lamberty Y., Margineanu D.G., and Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2 (2001) 454-459
28. Lawrence N.S., Williams A.M., Surguladze S., Giampietro V., Brammer M.J., Andrew C., et al. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry 55 (2004) 578-587
29. Marangell L.B., Dennehy E.B., Wisniewski S.R., Bauer M.S., Miyahara S., Allen M.H., et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 69 (2008) 916-922
30. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., and Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25 (2001) 585-600
31. Murphy D.L., Brodie H.K., Goodwin F.K., and Bunney Jr. W.E. Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature 229 (1971) 135-136
32. O'Donnell K.C., and Gould T.D. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 31 (2007) 932-962
33. Otto M.W., Simon N.M., Wisniewski S.R., Miklowitz D.J., Kogan J.N., Reilly-Harrington N.A., et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 189 (2006) 20-25
34. Peet M., and Peters S. Drug-induced mania. Drug Safety 12 (1995) 146-153
35. Ripoll N., Hascoet M., and Bourin M. The four-plates test: anxiolytic or analgesic paradigm?. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 873-880
36. Rushton R., and Steinberg H. Combined effects of chlordiazepoxide and dexamphetamine on activity of rats in an unfamiliar environment. Nature 211 (1966) 1312-1313
37. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356 (2007) 1711-1722
38. Shannon H.E., and Love P.L. Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav 7 (2005) 620-628
39. Simon N.M., Otto M.W., Wisniewski S.R., Fossey M., Sagduyu K., Frank E., et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 161 (2004) 2222-2229
40. Simon G.E., Hunkeler E., Fireman B., Lee J.Y., and Savarino J. Risk of suicide attempt and suicide death in patients treated for bipolar disorder. Bipolar Disord 9 (2007) 526-530
41. Truman C.J., Goldberg J.F., Ghaemi S.N., Baldassano C.F., Wisniewski S.R., Dennehy E.B., et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 68 (2007) 1472-1479
42. Young J.W., Minassian A., Paulus M.P., Geyer M.A., Perry W., Young J.W., et al. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31 (2007) 882-896